[1] Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2017, 389:56-66.
[2] Schütte K, Tippelt B, Schulz C, et al. Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clin Nutr, 2015, 34:1122-1127.
[3] 王代宏, 王芳元, 王伟, 等. 原发性肝癌手术前后营养风险筛查及临床分析. 临床外科杂志, 2013, 21:933-936.
[4] Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology, 2016, 150:835-853.
[5] Iritani S, Imai K, Takai K, et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J Gastroenterol, 2015, 50:323-332.
[6] 陈博, 徐阿曼, 胡孔旺, 等. 围手术期消化道肿瘤患者营养风险与营养支持情况分析. 安徽医药, 2016, 20:271-274.
[7] Tohme S, Chidi AP, Sud V, et al. Prognostic nutritional index is associated with survival in patients with unresectable hepatocellular carcinoma treated with radioembolization. J Vasc Interv Radiol, 2017, 28:470-472.
[8] Okamura Y, Ashida R, Ito T, et al. Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma. World J Surg, 2015, 39:1501-1509.
[9] Chen L, Chen Y, Wang X, et al. Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis. Nutr J, 2015, 14:67.
[10] Imanaka K, Ohkawa K, Tatsumi T, et al. Impact of branched‐chain amino acid supplementation on survival in patients with advanced hepatocellular carcinoma treated with sorafenib: A multicenter retrospective cohort study. Hepatol Res, 2016, 46:1002-1010. |
